Syndax Pharmaceuticals a promising commercial biotech with multiple approved drugs - Price target $20-56 (M&A possible)
Hello,
I'll get to the chase and I'll try to keep it short. No AI usage (Only for formatting so it's easier to read), however do your own DD. My position is 311 contracts of 2026 OTM calls and planning to add more.
https://i.imgur.com/U3hXCUd.png
---
**TLDR:**
- Small-cap oncology / hematology biotech that now has two commercial products: **Revuforj® (revumenib)**, a menin inhibitor for select AML patients, and **Niktimvo™ (axatilimab-csfr)** (co-developed with Incyte) for chronic GVHD.
- Has over **$456 million** cash in hand. Syndax expects that its operating expense base will remain stable over the next few years. As a result, Syndax expects that its cash, cash equivalents and short- and long-term investments, combined with its anticipated product revenue and interest income, will enable the company to reach profitability. Meaning **no dilution** for investors.
- Received **U.S. FDA approval for Revuforj on October 24, 2025**, for the treatment of R/R acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. Revuforj is now the **first and only FDA-approved therapy** for both R/R AML with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation.
- Has Analyst price targets ranging from $18 to $56. With almost all recommending at least a "Buy"
---
If you go and look at their revenue multiple so far — it continues to trade at a fraction of the valuation of peer commercial-stage oncology & non-oncology focused bios with similar projected revenue profiles.
SNDX's year-to-date gross margin is **~96%**, which is ultra-competitive.
Revuforj is a **pill**. Niktimvo is administered via **IV**.
https://i.imgur.com/vOwjoez.png
---
**M&A?**
- Incyte CEO was on the board of Syndax for years before he got a job as the CEO of Incyte.
- Incyte faces a patent cliff issue in 2028.
- It already shares revenue with Syndax and Syndax drugs work great in synergy with Incyte.
- Incyte has over **$2.9B cash in hand.**
According to this analysis below:
https://i.imgur.com/dwgqvFz.png
We can estimate an **M&A value range**:
- **Lowest:** $20.48
- **Median:** $38.80
- **Highest:** $68.51
Note that Incyte’s recent earnings call hinted at M&A activity:
**Incyte earnings tidbits**
- **Niktimvo** continues to surpass expectations across all launch metrics
- 90% of US bone marrow centers have adopted, with all call centers placing repeat orders year to date
- 80% of patients who started treatment in first quarter of launch are still on treatment today
- Captured 13% of 3rd line+ GVHD opportunity in just the first nine months on the market
- Primarily being used in 4th line, with increasing preference and utilization in 3rd line
- Real-world safety & efficacy equally as impressive as the clinical data
- Actively studying Niktimvo in earlier lines of therapy to create a steroid-free regimen to shift standard of care (**Jakafi combination**, has the potential to deliver benchmark efficacy and steroid tapering)
- **“Franchise” strategy to increase addressable market share and strengthen leadership position in GVHD**
---
**Risks**
- **KURA's drug approval** is on November 30th. It competes with the recently approved SNDX drug patient subset.
- While it’s marginally safer, it has lower efficacy.
- If it gets the same label or a CRL, this risk would be eliminated.
---
**Upcoming Catalysts**
- **Nov 10–20:** Upcoming investor events — watch for M&A hints or if they're offering more detail on the data for ASH.
- **Nov 30:** KURA's drug decision — if it gets a label or CRL then SNDX will benefit.
- **Dec 6–8 (ASH Conference):** Major new phase data and abstracts. First look into the data for the Rev + ven + aza combo, which is critical.
- **Q1 2026:** Colon cancer phase 1 results — if successful, it could add $1B+ to SNDX TAM/value.
- If SNDX is bought before approval (likely), it’d add $300–500M due to the inherent FDA approval risk.
---
**Recent Business Highlights (from Q3 2025 Earnings Release)**
Source: https://ir.syndax.com/news-releases/news-release-details/syndax-reports-third-quarter-2025-financial-results-and-provides
---
### Revuforj® (revumenib)
- Achieved **$32.0M in Revuforj net revenue** in Q3 2025, a **12% increase** over Q2 2025.
- Total prescriptions in Q3 were ~850, a **25% increase** over Q2 2025.
- Received U.S. FDA approval (Oct 24, 2025) for R/R AML with NPM1 mutation — first and only FDA-approved therapy for both R/R AML with NPM1m and R/R acute leukemia with KMT2A translocation.
- Added to **NCCN Guidelines®** for AML as a **category 2A** recommended treatment option (Sept 18, 2025).
- 12 Revuforj abstracts, including 3 oral presentations, will be highlighted at **ASH 2025**.
**Ongoing and upcoming trials:**
- **EVOLVE-2 (Phase 3):** Revuforj + venetoclax + azacitidine (newly diagnosed NPM1m AML, unfit for intensive chemo).
- **SAVE (Phase 1/2):** Revuforj + venetoclax + decitabine/cedazuridine (NPM1m, KMT2Ar, NUP98r). Data from first cohort at ASH 2025.
- **Intensive chemo combos (Phase 1):** Revuforj + 7+3 → maintenance; preliminary data at ASH 2025.
- **BEAT AML:** Revuforj + venetoclax + azacitidine in older adults (≥60).
- **Break Through Cancer (Phase 2):** Revuforj + venetoclax for MRD elimination and extended PFS.
- **INTERCEPT (Phase 1):** Revuforj for MRD and early relapse in AML.
- **REVEAL trials (start-up):** Revuforj + SOC in newly diagnosed AML (NPM1m or KMT2A-r). Starting by end of 2025.
- Evaluating Revuforj in **metastatic MSS colorectal cancer** — data expected **Q1 2026**.
---
### Niktimvo™ (axatilimab-csfr)
- Achieved **$45.8M in Niktimvo net revenue** in Q3 2025, up **27%** over Q2 2025.
- Syndax and Incyte are co-commercializing Niktimvo (50/50 profit split).
- Syndax’s share of Niktimvo contribution in Q3 was **$13.9M** (reported as collaboration revenue).
- 11 Niktimvo abstracts (3 oral) to be showcased at **ASH 2025** — long-term benefit and tolerability data.
**Ongoing trials:**
- **Phase 2 (open-label):** Niktimvo + ruxolitinib (newly diagnosed cGVHD, ≥12 years).
- **Phase 3 (pivotal):** Niktimvo + corticosteroids (newly diagnosed cGVHD, ≥12 years).
- **MAXPIRe (Phase 2):** Niktimvo in idiopathic pulmonary fibrosis (IPF); enrollment to complete by end of 2025, topline data 2H 2026.
---
